Volume 32, Issue 6 (September 2021)                   Studies in Medical Sciences 2021, 32(6): 399-407 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-4941-en.html
MSc of Clinical Biochemistry, Tabriz University of Medical Science, Tabriz, Iran (Corresponding Author) , valilo.biomed@gmail.com
Abstract:   (2093 Views)
Background & Aims: Parkinson's disease is the second most commonly diagnosed neurological disease after Alzheimer's disease. Paraoxonase 1 enzyme is an antioxidant enzyme with two paraoxonase and aryl esterase activity, and the change in activity and concentration of this enzyme can contribute to Parkinson's disease. The N-acetyltransferase enzyme plays an important role in the detoxification of organophosphates, in which the N-acetyltransferase 2 enzyme plays an important role. The aim of this study was to evaluate the paraoxonase activity ratio to aryl esterase activity of paraoxonase enzyme and the frequency of N-acetyltransferase 2 enzyme polymorphisms in patients with Parkinson's disease.
Materials & Methods: In this case-control study, 80 cases (40 patients with Parkinson's disease and 40 control subjects) were studied. N-acetyltransferase-2 polymorphisms by the PCR-RFLP method were investigated using the relevant bound restriction enzymes. The serum level of paraoxonase 1 was determined by ELISA and enzyme activity of paraoxonase 1 was measured with spectrophotometric.
Results: The ratio of paraoxonase to Aryl esterase did not show any significant difference between the two groups (p >0.05). Significant differences were observed in the frequency of m1 polymorphism genotypes between control and patient groups (p <0.05). However, the prevalence of polymorphism genotypes m1 and m2 between the two groups did not show a significant difference (p> 0.05).
Conclusion: The results of this study showed that three N-acetyltransferase 2 polymorphisms, m1 polymorphism, as well as a decrease in serum levels and paraoxonase 1 activity, may contribute to the pathogenesis and etiology of Parkinson's disease.
Full-Text [PDF 525 kb]   (577 Downloads)    
Type of Study: case report | Subject: Neuroscience

1. Galvan A, Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol 2008;119(7):1459-74. [DOI:10.1016/j.clinph.2008.03.017] [PMID] [PMCID]
2. Balestrino R, Schapira A. Parkinson disease. Eur J Neurol 2020;27(1):27-42. [DOI:10.1111/ene.14108] [PMID]
3. Keane P, Kurzawa M, Blain P, Morris C. Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis 2011;2011:716871. [DOI:10.4061/2011/716871] [PMID] [PMCID]
4. Hayes MT. Parkinson's disease and parkinsonism. Am J Med 2019;132(7):802-7. [DOI:10.1016/j.amjmed.2019.03.001] [PMID]
5. Chung K, Dawson TM, Dawson VL. Nitric oxide, S-nitrosylation and neurodegeneration. Cell Mol Biol (Noisy-le-grand) 2005;51(3):247-54. [Google Scholar]
6. Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol 2005; (170):263-300.7. [DOI:10.1007/3-540-27661-0_9] [PMID]
7. 7 Mota A, Taheraghdam A, Valilo M. Paraoxonase1 and its relationship with Parkinson's disease. Brain 2019;4:1-6. [DOI:10.15761/JBN.1000120]
8. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107(22):2775-9. [DOI:10.1161/01.CIR.0000070954.00271.13] [PMID]
9. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998;18(10):1617-24. [DOI:10.1161/01.ATV.18.10.1617] [PMID]
10. Seres I, Paragh G, Deschene E, Fulop Jr T, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004;39(1):59-66. [DOI:10.1016/j.exger.2003.08.001] [PMID]
11. Singh S, Kumar V, Singh P, Banerjee BD, Rautela RS, Grover SS, et al. Influence of CYP2C9, GSTM1, GSTT1 and NAT2 genetic polymorphisms on DNA damage in workers occupationally exposed to organophosphate pesticides. Mutat Res Genet Toxicol Environ Mutagen 2012;741(1-2):101-8. [DOI:10.1016/j.mrgentox.2011.11.001] [PMID]
12. Salazar-González RA, Zhang X, Doll MA, Lykoudi A, Hein DW. Role of the human N-acetyltransferase 2 genetic polymorphism in metabolism and genotoxicity of 4, 4′-methylenedianiline. Arch Toxicol 2019;93(8):2237-46. [DOI:10.1007/s00204-019-02516-4] [PMID] [PMCID]
13. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19(2):330-5. [DOI:10.1161/01.ATV.19.2.330] [PMID]
14. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101(8):1581-90. [DOI:10.1172/JCI1649] [PMID] [PMCID]
15. Kim DS, Burt AA, Ranchalis JE, Richter RJ, Marshall JK, Nakayama KS, et al. Dietary cholesterol increases paraoxonase 1 enzyme activity. J Lipid Res 2012;53(11):2450-8. [DOI:10.1194/jlr.P030601] [PMID] [PMCID]
16. Kokouva M, Koureas M, Dardiotis E, Almpanidou P, Kalogeraki A, Kyriakou D, et al. Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population. Toxicology 2013;307:12-6. [DOI:10.1016/j.tox.2012.07.003] [PMID]
17. Mota A, Hemati-Dinarvand M, Taheraghdam AA, Nejabati HR, Ahmadi R, Ghasemnejad T, et al. Association of Paraoxonse1 (PON1) Genotypes with the Activity of PON1 in Patients with Parkinson's Disease. Acta Neurol Taiwan 2019;28(3):66-74. [Google Scholar]
18. Rael LT, Bar-Or R, Aumann RM, Slone DS, Mains CW, Bar-Or D. Oxidation-reduction potential and paraoxonase-arylesterase activity in trauma patients. Biochem Biophys Res Commun 2007;361(2):561-5. [DOI:10.1016/j.bbrc.2007.07.078] [PMID]
19. Benmoyal-Segal L, Vander T, Shifman S, Bryk B, Ebstein R, Marcus E-L, et al. Acetylcholinesterase/ paraoxonase interactions increase the risk of insecticide‐induced Parkinson's disease. FASEB J. 2005;19(3): 452-4. [DOI:10.1096/fj.04-2106fje] [PMID]
20. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1* 10 allele with higher N-acetylation activity in bladder and colon tissue. Clin Cancer Res 1995;55(22): 5226-9. [Google Scholar]
21. Weber W, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985;37:25-79. [PMID]
22. Kim W-J, Lee H-L, Lee S-C, Kim YT, Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 2000;164(1):209-13. [DOI:10.1016/S0022-5347(05)67496-4]
23. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42(11):978-84. [DOI:10.1038/ng.687] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb